Risdiplam Price Disparity in India vs China, Pakistan: SC Issues Notice to Roche Farhat Nasim6 April 2025 2:00 PM ISTIt was submitted that why can't the Indian government negotiate with Roche to make the medicine for the rare disorder available at a cheaper rate.
India's Medical Device Exports to US Hit by 26% Reciprocal Tariff: AiMeD Raises Concerns Farhat Nasim6 April 2025 11:15 AM ISTNew Delhi: The imposition of a 26% reciprocal tariff by the United States on Indian medical device exports has raised serious concerns within the...
Setback to Roche: Plea Against Natco on Risdiplam Patent Rejected by Delhi HC Farhat Nasim25 March 2025 5:31 PM ISTNew Delhi: In a major relief to Indian drugmaker Natco Pharma, the Delhi High Court has rejected an interim injunction plea filed by Swiss...
USFDA Approves Roche's Evrysdi Tablet for Spinal Muscular Atrophy Farhat Nasim15 Feb 2025 10:45 AM ISTEvrysdi is the only non-invasive disease-modifying treatment for SMA.
Natco Pharma submits application with USFDA for Risdiplam for Oral Solution Ruchika Sharma26 Nov 2024 3:21 PM ISTHyderabad: Natco Pharma, an Indian pharmaceutical company has announced the submission of an Abbreviated New Drug Application (ANDA)...
Royalty Pharma to pay USD 1 billion for Roche SMA drug royalties Ruchika Sharma22 Oct 2023 10:00 AM ISTPTC said it plans to use the proceeds from the deal to pay back its debt from Blackstone Life Sciences and to fund planned operations.
Roche presents positive results for spinal muscular atrophy treatment Evrysdi in babies Ruchika Sharma8 Oct 2023 11:00 AM ISTBasel: Roche has presented positive results from the primary analysis of the ongoing RAINBOWFISH study assessing the efficacy and safety of Evrysdi...
Roche Evrysdi gets European Commission nod for babies under two months old with spinal muscular atrophy Ruchika Sharma30 Aug 2023 3:00 PM ISTBasel: Roche has announced that the European Commission has approved the extension of the Evrysdi (risdiplam) European Union (EU) marketing...
Roche Evrysdi gets CHMP recommendation for babies under two months old with spinal muscular atrophy Ruchika Sharma24 July 2023 3:30 PM ISTEvrysdi is currently approved in the EU for the treatment of patients aged two months or older,
Risdiplam improves motor function and milestones in infants: Lancet Jacinthlyn Sylvia3 Nov 2022 10:00 AM ISTA new study published in The Lancet Neurology suggests that over the course of a 24-month treatment with risdiplam, motor function and developmental...
Roche gets USFDA nod for spinal muscular atrophy therapy Evrysdi for babies below 2 months Ruchika Sharma31 May 2022 4:02 PM ISTOf the babies with 2 or 3 copies of the SMN2 gene (n=6), 100% were able to sit after one year of treatment with Evrysdi, 67% could stand and 50% of...
Once-Daily Risdiplam beneficial in patients with Types 2 and 3 SMA: Lancet Dr. Shravani Dali19 Jan 2022 9:00 AM ISTOnce-Daily Risdiplam is beneficial in patients with Types 2 and 3 spinal muscular atrophy (SMA), according to a recent study published in the Lancet....
